ORG Partners LLC Invests $32,000 in Revvity, Inc. (NYSE:RVTY)

ORG Partners LLC purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY) in the fourth quarter, Holdings Channel reports. The firm purchased 290 shares of the company’s stock, valued at approximately $32,000.

Several other institutional investors have also added to or reduced their stakes in RVTY. Gladius Capital Management LP increased its stake in shares of Revvity by 84.1% during the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after buying an additional 106 shares during the period. CENTRAL TRUST Co bought a new stake in Revvity in the fourth quarter valued at $27,000. JTC Employer Solutions Trustee Ltd purchased a new position in Revvity during the 4th quarter valued at $33,000. Headinvest LLC bought a new position in Revvity in the 3rd quarter worth $57,000. Finally, DB Wealth Management Group LLC purchased a new stake in shares of Revvity in the 4th quarter worth about $79,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

Shares of NYSE:RVTY opened at $100.30 on Wednesday. The business has a fifty day moving average price of $104.96 and a 200-day moving average price of $101.71. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. The company has a market capitalization of $12.39 billion, a PE ratio of 18.24, a PEG ratio of 2.69 and a beta of 1.09. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $137.09.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. The business had revenue of $695.90 million during the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. As a group, equities analysts expect that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. Revvity’s payout ratio is currently 5.09%.

Analysts Set New Price Targets

Several brokerages recently issued reports on RVTY. Barclays boosted their price target on shares of Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Evercore ISI raised Revvity from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Raymond James lifted their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Stifel Nicolaus increased their price objective on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Finally, UBS Group lowered Revvity from a “buy” rating to a “neutral” rating and raised their price objective for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.91.

Insider Activity at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is currently owned by insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.